Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).
Cytohistological confirmation is required for diagnosis of cancer. [+8]
Patients participated in clinical trials of equipment or drugs (signed informed... [+8]